A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective

Incorporating either PCV20 or PCV15/PPSV23 vaccines in routine vaccination programs for adults aged 50-64 years compared to vaccinating only adults with chronic conditions had an incremental budget impact of $6.5 and $9 billion, respectively, over three years. Budgetary impact was sensitive to number of vaccine doses, cost of vaccine per dose, vaccine coverage proportion and pneumococcal treatment cost across the overall population and sub-groups. Routine vaccination of 50-64-year-old age group was more economically favorable in Black adults sub-group analyses.